Budd-Chiari syndrome in a young female with factor V Leiden mutation: Successful treatment with lepirudin, a direct thrombin inhibitor

Thrombosis Research

Volumn 121, Issue 6, 2008, Pages 769-772

  Salmela, Birgitta ^a   Nordin, Arno ^a   Vuoristo, Matti ^a   Mäkisalo, Heikki ^a   Numminen, Kirsti ^a   Lassila, Riitta ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Anticoagulation; Thrombin; Thrombophilia; Venous thrombosis

Indexed keywords

AMINOTRANSFERASE; BLOOD CLOTTING FACTOR 5 LEIDEN; D DIMER; DALTEPARIN; LEPIRUDIN; VITAMIN K GROUP; WARFARIN;

ABDOMINAL DISTENSION; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASCITES; BLEEDING; BUDD CHIARI SYNDROME; CASE REPORT; CHOLECYSTECTOMY; CHRONIC CHOLECYSTITIS; COMPUTER ASSISTED TOMOGRAPHY; EPIGASTRIC PAIN; FEMALE; GASTROSCOPY; GENE MUTATION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER BIOPSY; LIVER FUNCTION; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARACENTESIS; PRIORITY JOURNAL; WEIGHT GAIN;

ADULT; ANTICOAGULANTS; ANTITHROMBINS; BUDD-CHIARI SYNDROME; CHOLECYSTITIS; DISEASE PROGRESSION; DRUG RESISTANCE; DRUG TOXICITY; FACTOR V; FEMALE; FOLLOW-UP STUDIES; HIRUDINS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MUTATION; ODDS RATIO; RECOMBINANT PROTEINS; THROMBOPHILIA; TREATMENT OUTCOME;

EID: 41749098597     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.08.008     Document Type: Article

References (19)

1. Denninger M.H., Chait Y., Casadevall N., Hillaire S., Guillin M.C., and Bezeaud A. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 31 (2000) 587-591
2. Janssen H.L., Garcia-Pagan J.C., Elias E., Mentha G., Hadengue A., Valla D.C., et al. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 38 (2003) 364-371
3. Valla D.C. The diagnosis and management of the Budd-Chiari syndrome: consensus and controversies. Hepatology 38 (2003) 793-803
4. Slakey D.P., Klein A.S., Venbrux A.C., and Cameron J.L. Budd-Chiari syndrome: current management options. Ann Surg 233 (2001) 522-527
5. Ruh J., Malago M., Busch Y., Lang H., Paul A., Verhagen R., et al. Management of Budd-Chiari syndrome. Dig Dis Sci 50 (2005) 540-546
6. Plessier A., Sibert A., Consigny Y., Hakime A., Zappa M., Denninger M.H., et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology 44 (2006) 1308-1316
7. Valla D.C. Hepatic vein thrombosis (Budd-Chiari syndrome). Semin Liver Dis 22 (2002) 5-14
8. Weitz J.I., Leslie B., and Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 97 (1998) 544-552
9. Puurunen M., and Lassila R. Successful treatment of mesenterial venous thrombosis with recombinant hirudin-a report of five cases. Thromb Res 118 (2006) 241-245
10. Lubenow N., Eichler P., Lietz T., Greinacher A., and Hit Investigators G. Lepirudin in patients with heparin-induced thrombocytopenia-results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 3 (2005) 2428-2436
11. Janssen H.L., Meinardi J.R., Vleggaar F.P., van Uum S.H., Haagsma E.B., van Der Meer F.J., et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 96 (2000) 2364-2368
12. Deltenre P., Denninger M.H., Hillaire S., Guillin M.C., Casadevall N., Briere J., et al. Factor V Leiden related Budd-Chiari syndrome. Gut 48 (2001) 264-268
13. Murad S.D., Valla D.C., de Groen P.C., Zeitoun G., Hopmans J.A., Haagsma E.B., et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 39 (2004) 500-508
14. Agnelli G., Renga C., Weitz J.I., Nenci G.G., and Hirsh J. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. Blood 80 (1992) 960-965
15. Badimon L., Badimon J.J., Lassila R., Heras M., Chesebro J.H., and Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin, and calcium chelation. Blood 78 (1991) 423-434
16. Schiele F., Lindgaerde F., Eriksson H., Bassand J.P., Wallmark A., Hansson P.O., et al. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study Group. Thromb Haemost 77 (1997) 834-838
17. Di Nisio M., Middeldorp S., and Buller H.R. Direct thrombin inhibitors. N Engl J Med 353 (2005) 1028-1040
18. Lubenow N., Eichler P., Lietz T., Farner B., and Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 104 (2004) 3072-3077
19. Begelman S.M., and Deitcher S.R. Outpatient management of venous thromboembolic disease with subcutaneous lepirudin: a case report. J Thromb Thrombolysis 13 (2002) 183-185